Understanding LADA: Why Doctors Are Looking for Better Ways to Identify This Overlooked Form of Diabetes

LADA stands for latent autoimmune diabetes in adults. It's a form of diabetes that doesn't fit neatly into the usual categories. It shares some features with Type 1 diabetes—including an autoimmune process where the body's immune system attacks insulin-producing cells—but it develops slowly in adults, more like Type 2 diabetes does. Because LADA falls somewhere between these two well-known forms, it's often misdiagnosed, sometimes initially labeled as Type 2 when it is actually autoimmune in nature.

Getting the right diagnosis matters. Understanding whether someone has LADA versus Type 2 diabetes can affect how they are treated and managed over time. That's why researchers are working to find clearer, more reliable ways to identify LADA early.

To improve diagnosis, scientists are turning to proteomics—the study of proteins in the body. Blood proteins and immune markers can act as windows into what's happening in a person's body. Researchers have identified several markers that appear different in people with LADA compared to those with Type 1 or Type 2 diabetes. These include adiponectin, interferons, and inflammatory proteins like IL-6 and CCL2.

The theory is promising: if doctors could measure these markers in a patient's blood, they might be able to more accurately determine whether someone has LADA rather than another form of diabetes. This could lead to earlier, more precise diagnoses and potentially better-tailored treatment approaches.

Current research suggests that LADA has a biomarker profile that is genuinely intermediate—showing some patterns seen in Type 1 diabetes and others seen in Type 2. This dual nature helps explain why LADA can be so difficult to recognize. Some markers suggest immune system activation, while others point to the kind of low-grade inflammation and metabolic changes seen in Type 2 diabetes.

However, researchers emphasize that the evidence remains mixed and incomplete. Studies have involved small numbers of patients, often looked at people at just one point in time rather than following them over months or years, and haven't yet been rigorously validated in clinical settings. In other words, while the findings are interesting, they are not yet solid enough to use in everyday medical practice.

Before any of these biomarkers can become routine diagnostic tools, much more work is needed. Researchers call for larger studies that follow patients over longer periods, more careful characterization of who has LADA and who doesn't, and thorough testing to confirm that biomarker patterns truly help doctors make better decisions.

The authors of this research review are cautiously hopeful. They see real potential in several markers, but they stress that their current role should be viewed as exploratory—useful for guiding future research rather than for clinical use today. As studies continue, a clearer picture of LADA's biology may emerge, eventually offering a better path to diagnosis and care.

Source: International journal of molecular sciences. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.